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Abstract
Opioid overdose is the most common cause of accidental death in the United States and
no policy response has been able to contain this epidemic to date. We examine whether
local access to medical cannabis can reduce opioid-related mortality. Using a unique
data set of medical cannabis dispensaries combined with county-level mortality data,
we estimate the effect of dispensaries operating in a county on the number of overdose
deaths. We find that counties with dispensaries experience 6% to 8% fewer opioid-
related deaths among non-Hispanic white men. Mortality involving heroin declines by
approximately 10% following the opening of a dispensary.
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1 Introduction
With over 42,000 deaths due to opioid overdoses in 2016, the ongoing opioid epidemic is
arguably the most pressing public health crisis in the U.S. It has even contributed to a re-
versal in the long-term trend of declining mortality rates among middle-aged non-Hispanic
whites (Case and Deaton, 2015). No policy has been successful in reducing opioid-related
mortality overall, which is driven by an exponential increase in heroin and fentanyl (a syn-
thetic opioid) overdoses in recent years. While not intended as a remedy for the opioid crisis,
several studies have shown that the legalization of medical cannabis may alleviate this epi-
demic. These existing studies focus on the role of state laws that legalize the consumption
of cannabis for medical purposes. In contrast, we depart from the state-level approach by
allowing for within-state heterogeneity in availability of medical cannabis to quantify the
extent to which local access to cannabis impacts opioid-related mortality rates. This more
granular approach allows us to examine how this relationship depends on the presence med-
ical cannabis dispensaries rather than on the legal status of medical cannabis on the state
level.
Using a novel dataset that documents the locations and opening and closing dates of
medical cannabis dispensaries, we capture changes in the effective costs of drug consumption
that follow the implementation of medical cannabis laws (MCL). Specifically, we exploit the
variation in the presence of dispensaries over time and within and across states to estimate
the relationship between access to medical cannabis and opioid-related mortality. In addition
to the legal consequences of drug acquisition, geographic proximity plays a crucial role. While
state-level MCL reduce the legal costs associated with possessing and consuming cannabis,
they do not, per se, affect the relative costs related to searching for or acquiring the drug.
Under the assumption that there is a certain degree of substitutability between opioids and
cannabis, the effect of an MCL on the effective price of cannabis (relative to opioids) should
be strongest in areas directly exposed to dispensaries.1
Studies that rely on state-level variation in MCL cannot account for within-state het-
erogeneity in the cost of accessing cannabis. For instance, given that rural and urban areas
differ in their access to dispensaries, there is no reason to believe that they should be equally
affected by a state-level MCL. To the extent that dispensaries are not uniformly distributed
within a state, it is difficult to infer the effects of cannabis legalization from policy variation
on the state level. From a public policy perspective, those estimates may provide policy
makers with conclusions about the convenience of MCL which are not grounded in the ef-
1By “effective price” we refer to the price inclusive of costs associated with legality, search, and trans-
portation.
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fects of cannabis per se. By capturing the effect of the presence of a dispensary on opioid
mortality at the county level, our estimates come closer to capturing the “true” effect of
cannabis on opioid-related mortality.
Departing from existing studies, our research design compares counties with and without
dispensaries within the same state. Therefore, we are not only able to control for the legal
status of medical cannabis but also for any unobserved factors that may drive differences in
opioid use between states. In addition, we allow for persistent unobserved county-specific
differences and state-specific trends in opioid mortality. Hence, our identification strategy
relies on temporal variation in the access to medical cannabis within counties. This research
design allows us to isolate the impact of a dispensary on opioid-related deaths more effectively
than prior literature and brings our estimates closer to providing a causal interpretation.
Furthermore, our work addresses the criticism that the state-level analyses used in existing
studies do not provide conclusive evidence because unobserved differences between states
could explain the estimated relationship between medical cannabis legalization and opioid
mortality (Finney, Humphreys, and Harris, 2015; Hall et al., 2018).
Using time variation in dispensary opening and estimating Poisson regressions of county-
level deaths due to opioid overdoses, we find a significant decline in mortality in counties
where dispensaries are present. While medical cannabis dispensaries reduce opioid-related
mortality overall, our results are strongest for heroin overdoses. Specifically, we find that
mortality related to any opioids and prescription opioids declines by 6% to 8%. For heroin,
the reduction in mortality amounts to 10%, although this effect is less precisely estimated.
Importantly, these effects are limited to counties where dispensaries opened and do not apply
to non-dispensary counties in states with that have legalized medical cannabis. In fact, with
the exception of heroin-related overdoses, MCL themselves have a positive effect on opioid-
related mortality. That is, while legalizing medical cannabis is not associated with lower
levels of opioid overdose mortality, the presence of dispensaries has a large negative impact
on the number of opioid-related deaths.
These estimates imply that 10 per 100,000 (8.5%) fewer opioid-related deaths would
have occurred between 1999 and 2015 if states that legalized medical cannabis during this
period had had dispensaries in all counties as soon as the MCL came into effect. Our results
have direct policy implications since we find that MCL lead to a reduction in opioid-related
deaths that is limited to counties where access to medical cannabis is facilitated through the
presence of dispensaries.
As of October 2018, 31 states and the District of Columbia have legalized the use of
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cannabis for medical purposes.2 However, legal markets were relatively small until 2009
when the federal government issued the Ogden Memorandum stating that federal resources
would no longer be used to prosecute individuals in compliance with state medical cannabis
laws (Ogden, 2009). In the wake of the Ogden Memorandum, medical cannabis dispensaries
began opening up across multiple states that had legalized medical cannabis.3 The existing
literature use state-level variation in MCL to assess the effect of medical cannabis legalization
on opioid-related outcomes. For example, Bradford and Bradford (2016), Bradford and
Bradford (2017), Bradford et al. (2018), and Wen and Hockenberry (2018) show that MCL
lower prescriptions of opioid analgesics. Again using state-level policy variation, Bachhuber
et al. (2014) and Powell, Pacula, and Jacobson (2018) find that MCL reduce opioid-related
mortality. Powell, Pacula, and Jacobson (2018) also estimate that the effect of MCL on
opioid overdoses is mostly driven by whether dispensaries are active and legal on the state
level but do not account for sub-state-level variation in access to cannabis. In contrast to
these two studies, Pohl (2018) shows that the effect of MCL are sensitive to the inclusion of
state-specific time trends. In an important departure from the common state-level analysis,
Smith (2017) estimates that counties with medical cannabis dispensaries experience fewer
opioid-related admissions to drug treatment facilities conditional on MCL.
As a possible challenge to the substitutability from opioids to cannabis, the “gateway
hypothesis” postulates that cannabis consumption eventually leads to use of harder drugs
(Kandel, 1975). While this hypothesis is widely accepted to be true, the evidence in its favor
is mixed (Fergusson, Boden, and Horwood, 2006; Van Gundy and Rebellon, 2010). Instead,
the observed correlation between cannabis and hard drug use within individuals can be ex-
plained by pre-existing traits that increase an individual’s propensity to use drugs in general
(Morral, McCaffrey, and Paddock, 2002; Hall and Lynskey, 2005). Moreover, Robins et al.
(2010) finds that former heroin users may substitute towards cannabis. Preliminary evi-
dence suggests that cannabidiol, a non-psychoactive cannabis compound, can reduce craving
among heroin users and may therefore serve a role in mitigating the opioid epidemic (Hurd
et al., 2015; Hurd, 2017). It is therefore possible that facilitating access to medical cannabis
through dispensaries lowers opioid consumption and thus associated mortality. Our findings
directly support this hypothesis.
Until recently, the majority of overdoses were caused by prescription opioid analgesics
such as OxyContin. However, it is common for heavy users of prescription opioids to switch
to heroin (Compton, Jones, and Baldwin, 2016). As a result, heroin has become the most
2In addition, nine states and the District of Columbia have legalized cannabis for recreational use.
3See Smith (2017) for a detailed account of medical cannabis legalization and especially the emergence
of dispensaries.
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common drug involved in overdose deaths in recent years, at least among non-Hispanic white
men. Most recently, abuse of synthetic opioids such as fentanyl have increased dramatically
and exacerbated the impact of the opioid epidemic. The involvement of multiple drugs may
require more complex policy responses. Whereas prescription drug monitoring programs
(PDMP) have had some success in reducing consumption of and mortality related to pre-
scription opioids (Paulozzi, Kilbourne, and Desai, 2011; Patrick et al., 2016; Buchmueller
and Carey, 2018; Dave, Grecu, and Saffer, 2017), these programs cannot prevent utilization
of illicit opioids such as heroin or synthetic opioids sold on the black market. Policies that
are aimed at reducing the adverse effects of opioids in general—such as naloxone access laws
and Good Samaritan laws—have led to mixed results (Rees et al., 2017) or may even be
counterproductive (Doleac and Mukherjee, 2018). In particular, there is no policy to date
that is successful in lowering utilization and mortality related to heroin, one of the main
drivers of the opioid epidemic in recent years. Chu (2015) provides evidence that MCL en-
actments are associated with fewer treatment admissions for heroin addiction. However, his
sample period ends in 2011 and does not observe the recent increase in heroin abuse. Our
results imply that facilitating local access to medical cannabis may constitute a policy that
is successful at lowering heroin-related mortality.
2 Data
We use restricted-use individual mortality data with county identifiers from the Centers for
Disease Control and Prevention’s National Vitality Statistics System. The data contain in-
formation on multiple causes of death, demographics, and county of residence for the universe
of deaths in the United States from 1999 to 2015. Using these data, we calculate annual
county-level opioid overdose mortality levels and rates among non-Hispanic white men aged
15 to 54 as follows. First, we select records for which the underlying cause of death is classi-
fied as “Accidental poisoning” (ICD10 codes X40 to X44), “Intentional self-poisoning” (X60
to X69), “Assault by drugs, medicaments and biological substances” (X85), or “Poisoning
with undetermined intent” (Y10 to Y14). Among these records, we designate deaths with a
contributing cause of death classified as “Poisoning by and adverse effect of heroin” (ICD10
code T40.1), deaths with a contributing cause of death classified as “Poisoning by, adverse
effect of and underdosing of other opioids” (T40.2), and “Poisoning by, adverse effect of
and underdosing of other synthetic narcotics” (T40.4) as deaths due to heroin overdoses,
prescription opioid overdoses, and synthetic opioid overdoses, respectively. We also define
deaths with a contributing cause of deaths involving any opioid or unspecified narcotics
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Figure 1: Number of deaths due to opioid overdoses among non-Hispanic white men aged
15 to 54 per year, from 1999 to 2015.
(T40.0 to T40.4 and T40.6) as deaths related to any opioid. In addition to death records
that specify a particular type of narcotic, we identify potential heroin- and opioid-related
deaths among deaths that were classified as “Poisoning by other and unspecified drugs,
medicaments and biological substances” (T50.9) using the imputation method proposed by
Ruhm (2018). That is, we estimate year-specific probit regressions that use demographics
and location and time of death as explanatory variables to predict whether a death classified
as caused by an unspecified drug is actually related to a opioid or heroin overdose.
We then limit the sample to non-Hispanic white men who were aged 15 to 54 at the time
of their death.4 To obtain county-level mortality levels, we sum all deaths due to any opioid,
prescription opioid, heroin, and synthetic opioid overdoses, respectively, by year and county
of residence. Annual numbers of deaths due to opioid overdoses from 1999 to 2015 appear
in Figure 1. The graph shows a sharply increasing trend in opioid-related mortality in this
demographic group, increasing from 5,000 per year in 1999 to 17,500 in 2015. While the first
10 years of this period were characterized by rising overdose mortality involving prescription
opioids, heroin-related overdoses have sharply increased since 2010, and the number of deaths
488% of all white non-hispanic men who died from any opioid overdose were between 15 and 54 years
old at the time of their death.
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Table 1: Number of Counties With Medical Cannabis Dispensaries
Total Counties Counties With Dispensaries
Pre-2009 2009 2010 2011 2012 2013 2014 2015
Arizona 15 0 0 0 0 0 4 14 15
California 58 23 27 38 44 46 46 46 47
Colorado 64 2 4 29 31 30 31 34 37
Connecticut 8 0 0 0 0 0 0 0 4
Washington DC 1 0 0 0 0 0 0 1 1
Maine 16 0 0 0 0 4 8 8 8
Michigan 83 0 0 7 17 24 21 18 18
Montana 56 0 0 4 5 4 4 5 6
Nevada 17 0 0 1 1 1 1 1 1
New Jersey 21 0 0 0 0 0 1 3 3
New Mexico 33 0 0 2 6 7 7 7 10
Oregon 36 0 0 4 11 12 12 13 19
Rhode Island 5 0 0 0 0 0 0 2 3
Vermont 14 0 0 0 0 0 0 3 4
Washington 39 0 0 3 8 9 15 18 25
Notes: At least one dispensary must be present for the entire calendar year for a county to be considered
a dispensary county.
due to synthetic opioid overdoses started increasing in 2013. In the last year of our sample
period, 2015, heroin was the most common drug involved in fatal overdoses, followed by
synthetic opioids and prescription opioids.
We combine county-level mortality rates with dispensary information collected from mul-
tiple sources by Smith (2017). Within medical cannabis states, dispensary openings (and
closings) are located using state registries, news articles, dispensary-locating websites, trans-
action reviews, social media accounts, and cannabis-friendly internet discussion boards.5 We
define a dispensary as any business that facilitates the transfer of cannabis for money. This
definition includes gray-market establishments that operated in states prior to dispensary
regulations being enacted.6 The first dispensaries in California opened shortly after the en-
actment of the state’s MCL in 1996. Colorado is the only other state to witness a dispensary
opening prior to the rapid expansion in 2009 following the Ogden memorandum. In total,
220 counties across 15 states experienced a dispensary opening for an entire calendar year
within the sample period. Table 1 shows the number of counties with operating dispensaries
5See Smith (2017) for details on the data collection.
6In contrast, Powell, Pacula, and Jacobson (2018) define operating and legally protected dispensaries on
the state level.
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Figure 2: Counties With MCL and Dispensaries.
Notes: Light blue counties are in states with an MCL and dark blue counties have at least one operating
medical cannabis dispensary.
by state and year. Most states with an MCL exhibit a relatively slow diffusion of dispen-
sary openings. By 2015, the majority of states only have dispensaries in a small fraction of
counties.
Figure 2 shows states where MCL were in effect and counties that had at least one oper-
ating dispensary in 2000, 2005, 2010 and 2015. In 2000, only five states (California, Oregon,
Washington, Alaska, and Maine) had legalized medical cannabis, and only a few counties
in California had operating dispensaries. By 2005, a few more states had implemented an
MCL, but dispensaries were still confined to California and two counties in Colorado. In
2010, after the Ogden Memorandum was issued, 13 states had legalized medical cannabis,
but dispensaries were not operating in many counties outside of California and Colorado.
Between 2010 and 2015, eight more states legalized medical cannabis, and in MCL states,
dispensaries opened in almost 200 counties.
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We combine the dispensary data with information on other relevant policies. Data on
MCL are obtained from a database maintained by procon.org. We retrieve information
on PDMP from Meinhofer (2017) and on naloxone access laws and Good Samaritan laws
from Rees et al. (2017). We also add data on beer tax rates from the Beer Institute’s
Brewers’ Almanac. Finally, we obtain county-level unemployment rates from the Local Area
Unemployment Statistics of the Bureau of Labor Statistics and county population data from
the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.
3 Empirical Strategy
Figure 2 illustrates the geographic (within and across states) and temporal variation within
counties that we use to determine the effect of dispensaries on opioid-related mortality. Most
states that legalized medical cannabis had counties with and without operating dispensaries,
and these dispensaries opened at different points in time. We use this source of variation to
implement a county-level difference-in-differences framework to estimate the causal impact
of dispensaries on opioid overdose mortality. In addition to county fixed effects that control
for time-invariant differences across counties, we include state-specific time trends to account
for the varying severity of the opioid epidemic. We also control for other policies aimed at
reducing opioid overdoses and economic conditions.
To focus on the role of dispensaries beyond the legal status of medical cannabis, we
restrict the sample to counties that were located in states that had implemented an MCL
before 2014. California is also omitted because the first dispensaries open there prior to our
sample period and cannabis delivery services are significantly more prevalent in California
than in other MCL states. In robustness checks, we include counties in states that did not
have an MCL during the sample period and California.
We estimate the effect of medical cannabis dispensaries on opioid overdose mortality using
a Poisson regression model. Modeling county-level mortality as a Poisson process instead of
using an ordinary least squares regression is appropriate for two reasons. First, our outcome
variables contain many zeros. For example, 47% of county-year-level observations do not
experience an opioid-related death. Second, opioid overdose mortality is highly skewed with
a median of one death and a 99th percentile of 49 deaths per county and year. Using
mortality rates instead of levels as the outcome variable could have been an alternative, but
this would not change the large number of zeros. Moreover, mortality rates are also highly
skewed distribution. Deaths due to any opioids per 100,000 population have a median of 4.6
and a 99th percentile of 76, for instance.
9
We specify the following Poisson regression model:
ErYcsts “ exp pθDct ` pol1stβ ` γuect ` lnppopctq ` αc ` δt ` µs ˆ tq , (1)
where ErYcsts is the expected number of opioid-related deaths in county c, state s, and year
t. Dct is a dummy variable that takes on the value one if a medical cannabis dispensary was
operating in county c in year t. The vector polst includes policies that vary on the state level
(MCL, PDMP, naloxone access laws, Good Samaritan laws, Pill Mill Bills, and the beer tax
rate). County-level average annual unemployment rates are included as uect to control for
local level macroeconomic conditions, and popct is the non-Hispanic white male population
aged 15 to 54 residing in county c in year t. By setting the coefficient of lnppopctq to one we
implicitly adjust mortality levels for the size of the population at risk. Finally, αc is a county
fixed effect, δt is a year fixed effect, and µsˆ t is a state-specific linear time trend. We report
the estimated coefficients as incidence rate ratios, i.e. exp
´
θˆ
¯
etc., in the regression tables.
Since we include county fixed effects in the Poisson regression, we effectively drop counties
that did not have any opioid-related deaths throughout the sample period (Cameron and
Trivedi, 2005, p. 806). For overdose deaths related to any opioid, this exclusion affects 35
counties, out of which 2 had an operating medical cannabis dispensary. Mean population size
in the excluded counties is 847. It is therefore unlikely that excluding these counties from
the analysis has a substantial effect on the estimates. We nevertheless test the robustness
of our results by estimating our main specification with county random effects instead of
fixed effects, which allows us to include counties that never any experienced opioid-related
mortality during the sample period.
4 Results
4.1 Main Results
We first provide graphical evidence on the effect of medical cannabis dispensaries on opi-
oid overdose mortality. Specifically, we consider changes in unconditional mortality rates
between 2009 and 2015 in counties that did not have a dispensary in 2009. As shown in
Table 1, the period from 2009 to 2015 experienced the highest number of dispensary open-
ings. While opioid mortality rates likely increased in all counties during this period, we are
interested in whether this mortality growth was slower in counties with operating cannabis
dispensaries.
Figure 3 shows that counties where a dispensary opened between 2009 and 2015 indeed
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Figure 3: Mortality Rates Due to Opioid Overdoses Among Non-Hispanic White Men.
Notes: Each observation corresponds to one county. Only counties that did not have a medical cannabis
dispensary in 2009 are included. The left panels refer to counties that did not have a dispensary in 2015
and the right panels refer to counties where at least one dispensary opened between 2009 and 2015. The
lines indicate the best linear fit. The β1s in the panel headings show the estimated slope coefficients of
the respective fit lines.
experienced slower growth in mortality than counties that continued not having a dispensary.
On average, the mortality rate due to any opioid overdose increased by 0.07 per 100,000 pop-
ulation in dispensary-counties between 2009 and 2015 and by 0.37 in counties without a dis-
pensary as indicated by the respective slope coefficients of the best linear fit. The difference
between the slope coefficients is statistically significant with p “ 0.01. Prescription opioid
mortality rates increased by 0.05 in dispensary-counties and rose by 0.2 in non-dispensary
counties (p “ 0.25). For heroin overdoses, mortality rates increased by 0.61 and 0.98 per
100,000 population in counties with and without dispensaries, respectively (p “ 0.06). For
synthetic opioid overdoses, the respective average changes were 0.2 for dispensary-counties
and 0.35 for counties without dispensaries (p “ 0.50). The graphs overall suggest that opioid
overdose mortality increased slower in counties where a medical cannabis dispensary opened
than in counties without dispensaries. Aside from displaying a steeper relationship between
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2009 and 2015 mortality rates, Figure 3 also shows that counties without a dispensary had
higher overdose deaths rates on an absolute level. For instance, many more counties without
a dispensary had any-opioid mortality rates exceeding 50 per 100,000 population in 2015
than counties where a dispensary was operational.
Table 2 shows our main regression results. The coefficients from the Poisson regressions
are reported as incidence rate ratios, i.e. an estimate below one implies that the corresponding
regressor reduces mortality. For each mortality outcome, we estimate two separate regres-
sions. The first specification includes dummy variables for medical cannabis dispensaries
and policies that aim to reduce opioid mortality (PDMP, naloxone access laws, and Good
Samaritan laws) whereas the second specification also contains a dummy variable for MCL.
The dispensary coefficient in the first set of regressions measures the average marginal effect
of an operating dispensary compared to counties that did not have a dispensary independent
of whether there was an effective MCL. In contrast, in the second set of regressions, the
dispensary coefficient indicates the effect of a dispensary conditional on the legal status of
medical cannabis. Notice that we only include counties in this regression where medical
cannabis was legalized at some point between 2009 and 2015.
The regression results show that operating medical cannabis dispensaries generally reduce
mortality due to opioid overdoses. These effects are similar across the two specifications, i.e.
independent of whether we also control for the legal status of medical cannabis. The average
reduction in overdose mortality due to medical cannabis dispensaries equals 8.2% for any
opioids, 9.3% for prescription opioids, and 10.5% for heroin. Conditional on MCL status,
counties with dispensaries have 6.1% fewer deaths due to any opioid, 8.6% lower mortality
levels related to prescription opioids, and a 10.1% reduction in heroin-induced mortality
compared to counties without a dispensary. These estimates are statistically significant at
least at the 5% level for any and prescription opioids and at or close to the 10% level for heroin
(p “ 0.083 and p “ 0.103, respectively). In contrast, medical cannabis dispensaries have
no statistically significant effect on synthetic opioid overdose mortality. MCL themselves
have a positive effect on opioid-related mortality. Mortality due to any opioid, prescription
opioids, and synthetic opioids is 25.9%, 12.0%, and 21.3% higher in counties where medical
cannabis is legalized. Heroin-related mortality is a notable exception in that it is not affected
by MCL in a statistically significant manner. The joint effect of legalizing medical cannabis
and providing access through dispensaries on heroin overdose mortality is therefore negative
overall. While legalizing medical cannabis does not lower opioid overdose mortality, the
presence of dispensaries has a large negative impact on the number of opioid-related deaths.
This effect is particularly strong for heroin overdoses, which have not been successfully
12
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lowered by any other policy. It is worth emphasizing that this effect would not have been
captured with more aggregated data and it underscores the importance of a more granular
approach to measure the impact of access to medical cannabis on opioid-related mortality.
Other policies that states have implemented to contain the opioid epidemic such as pre-
scription drug monitoring programs, naloxone access laws, and Good Samaritan laws do not
appear to reduce opioid-related deaths. In some instances, these policies may even be associ-
ated with increased opioid mortality rates. These results are consistent with the literature.7
Finally, we use the regression results shown in Table 2 to predict how many fewer non-
Hispanic white men would have died between 2009 and 2015 if dispensaries had operated
in more counties. Based on our estimation sample of counties where medical cannabis was
legalized before 2014, we consider two alternative scenarios. Under the first exercise, we
assume that dispensaries started to operate in all counties as soon as a statewide MCL was
enacted. Under the second, the implementation of the MCL is assumed to have occurred in
2009 and we also assume that dispensaries open in all counties as soon as medical cannabis
is legalized, i.e. in 2009. Thus, our counterfactual predictions do not change states’ over-
all medical cannabis policies but only the timing of MCL implementations and dispensary
openings.
The results in Table 3 show that for all types of drugs except synthetic opioids, pre-
dicted mortality is lower under the two alternative predictions than under actual dispensary
and MCL status. For overdoses due to any opioid, opening dispensaries immediately after
legalizing medical cannabis would have reduced the number of deaths by 9.7 per 100,000
population, and legalizing medical cannabis and opening dispensaries in 2009 in counties
where medical cannabis was only legalized during part of the period would have prevented
another 5.4 per 100,000 overdose deaths. For comparison, the mean annual mortality rate
was 13.6 in these counties. For prescription opioids, the number of deaths would have de-
clined by 3.5 plus 1.6 per 100,000 and for heroin by 5.3 plus 2.1 per 100,000. The latter
decline exceeds the mean heroin mortality rate of 7.2 per 100,000 in 2015 when the number
of heroin overdose deaths was highest. For synthetic opioids, mortality rates would have
been slightly higher under the alternative predictions. Overall, these predictions show that
substantially fewer non-Hispanic white men would have died between 2009 and 2015 if (1)
all counties where medical cannabis was legal also had dispensaries and (2) the states that
legalized medical cannabis before 2014 had done so by 2009.
7See for instance Paulozzi, Kilbourne, and Desai (2011); Rees et al. (2017); Doleac and Mukherjee (2018),
and Li et al. (2014).
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Table 3: Predicted Opioid Overdose Mortality per 100,000 Non-Hispanic White Males
MCL-Counties Partial-MCL-
Without Disp. Counties
Actual All Actual All MCL
Disp. Disp. MCL and Disp.
(1) (2) (3) (4)
Any Opioids 117.22 107.61 65.81 60.41
Prescription Opioids 37.89 34.35 18.11 16.42
Heroin 47.13 42.19 18.66 16.71
Synthetic Opioids 23.33 23.14 6.66 6.00
Number of Counties 449 174
Notes: This table shows the total predicted numbers of overdose deaths per 100,000 population among
non-Hispanic white men for the years 2009 to 2015. The predictions are based on the regression results
shown in Table 2, columns (1), (3), (5), and (7). The first two columns refer to county-year observations
where an MCL was in effect but no dispensary was operating. Column (1) shows the predicted number
of deaths under the actual dispensary status and column (2) shows predicted mortality under the coun-
terfactual that these counties had an operating dispensary whenever medical cannabis was legalized.
The last two columns refer to county-year observations where no MCL was in effect (among counties
that had an MCL by 2014). Column (3) shows the predicted number of deaths under the actual MCL
and dispensary status. The counterfactual in column (4) assumes that these counties had an MCL and
an operating dispensary in all years.
4.2 Robustness Checks
We conduct four robustness checks for our main Poisson regression results. First, Table 4
shows regression results for the sample of all counties with at least one death related to
the respective opioid (excluding California again) instead of limiting the sample to counties
where medical cannabis was legalized between 1999 and 2015. In these regressions, medical
cannabis dispensaries have no statistically significant effect on opioid overdose mortality, but
the point estimates for prescription opioids and heroin point to a reduction in mortality due
to dispensaries. Since these regressions include a majority of counties that cannot have a
dispensaries because they are located in states that never legalized medical cannabis, we
prefer our main results in Table 2 that focus on counties were a dispensary was legally
possible at some point before 2015.
Second, we add counties in California, which legalized medical cannabis in 1996, i.e.
before the start of our sample period. Table 5 shows statistically insignificant coefficients
on county dispensary. For any opioids and heroin, the point estimates suggest a reduction
15
in mortality, however. These less precisely estimated effects may be due to the fact that
California mostly uses a delivery-based model for the sale of medical cannabis. Local effects
on the county level are therefore less relevant. Since our focus is on local access to medical
cannabis, we prefer our main results.
Third, we include quadratic state-specific time trends instead of linear time trends in the
regression shown in Table 6. Due to the steep increase in opioid-related mortality in recent
years, there is a concern that a linear time trend is unable to match this pattern and may
therefore lead to biased estimates. We find, however, that the estimated coefficients in Table
6 do not differ substantially from our main regression results. In contrast to Table 2, we
find a decline in mortality related to synthetic opioids, but it is not statistically significant.
Overall, these results suggest that controlling for state-specific linear time trends is sufficient.
Finally, Table 7 shows regression results based on a random effects Poisson model instead
of a Poisson regression that includes county fixed effects. The advantage of a random effects
model is that it allows us for the small number of counties that did not experience any
opioid-related mortality over our sample period, but it has the drawback that we need to
assume independence of the random effects from the covariates entering the model. The
results in Table 7 are slightly less precise than our main results, but overall we estimate
similar coefficients. One difference is that we find larger and more precisely estimated effects
of dispensaries on prescription opioid mortality.
5 Conclusion
As of now, no policy response has been successful in alleviating the opioid epidemic, the
most common cause of accidental death in the United States. Policies have been particularly
ineffective in reducing mortality due to heroin overdoses. Using a unique dataset of medical
cannabis dispensaries, we examine the effect increased access to cannabis has on opioid- and
heroin-related mortality rates at the county level.
With our more granular approach, we depart from prior literature and argue that changes
in cannabis access drive the negative relationship between cannabis and opioids. We find
that within MCL-adopting states, counties with dispensaries experience 6% to 8% fewer
opioid-related deaths among non-Hispanic white men, while mortality due to heroin over-
dose declines by more than 10%. These effects are smaller than the 20% to 25% reductions
in opioid-related mortality found by existing studies using a state-level approach (Bachhu-
ber et al., 2014; Powell, Pacula, and Jacobson, 2018). While the geographical coverage and
the sample periods in these studies prevent us from drawing direct comparisons, our gran-
16
ular approach can arguably better control for unobserved geographic heterogeneity, thereby
bringing our results closer to a causal interpretation.
Extrapolating our results implies that, for every 100,000 non-Hispanic white men, 10
fewer opioid-induced fatalities would have occurred between 2009 and 2015 if dispensaries
were present and operating in every county within each MCL state.
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